Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Thermo Fisher Scientific heads into its October 21 earnings release with analyst sentiment turning more constructive, even as the stock pulls back from a strong month and short positioning remains negligible.
The most noteworthy development this week came from the Street rather than the lending market. Barclays raised its price target on TMO from $650 to $750 this morning, keeping an Overweight rating, the second time the firm has lifted its target since July. That move follows UBS assuming coverage with a Buy and a $730 target in early September, and CLSA initiating at Outperform with a $748 target shortly after. The direction of travel is clear: the most recent analyst actions are bullish and carrying targets well above where the stock trades. At $656.58, the mean Street target of $668 implies limited upside on consensus math, but the recent cluster of upgrades and initiations suggests that number is being revised upward. One holdout is Piper Sandler, which carries a Neutral with a $600 target, and RBC remains at Sector Perform with a $580 target, both set in late July. Morgan Stanley is more positive at Overweight with a $650 target from the same period. The bulls point to life science solutions revenue growing at a projected 5.4% compound annual rate and EPS expanding at roughly 8.5% annually over the next four years. The bear case centres on margin deterioration: adjusted EBIT margins fell around 830 basis points between 2021 and 2024, and adjusted gross margins remain well below their 2019 peak.
Valuation reflects a market that is paying a quality premium but watching it carefully. The price-to-earnings multiple is running near 24.3x, up about 1.4 points over the past 30 days even as the stock dipped this week. EV/EBITDA is around 20.7x, down slightly on the week as the price retreated. Factor scores paint a mixed picture: forward EPS growth ranks in the 86th percentile of the universe, and the short score ranks in the 83rd, meaning very few names have less short pressure than TMO. Value, however, scores in the 29th percentile on EV/EBIT, reflecting the premium the market assigns to the franchise. The ORTEX short score itself is at 30.1, drifting slightly lower over the past two weeks, which is consistent with the broader easing in short interest.
Short positioning in TMO is not a meaningful part of the story here. Short interest has edged down about 1.7% over the past week to 1.28% of the free float, a low absolute level that has been trending down since a brief spike in mid-September when shares outstanding on loan climbed toward 6 million. They have since fallen back to around 4.8 million. Borrow conditions are equally unthreatening: cost to borrow is running at 0.40%, down from around 0.49% a week ago, and availability is at its maximum tracked reading, with roughly 272 million shares available to lend against fewer than 5 million borrowed. Options positioning is similarly neutral, with the put/call ratio at 0.83, effectively flat against its 20-day average of 0.83 and showing a z-score near zero. Neither the lending market nor the options market is flashing any particular caution.
The stock's one-week decline of 3.4% to $656.58 is not an outlier in the peer group. DHR is off 4.6% over the same stretch, IQV down 3.3%, and MEDP down 3.0%. RGEN stands out as the weakest, falling more than 10% on the week. CRL is the only peer showing a gain at around 3%. The broad-based weakness across life sciences tools names suggests the pullback in TMO reflects sector rather than stock-specific pressure.
Retail attention is running above its recent baseline, with the Wikipedia-views signal registering a z-score of 1.4 against TMO's own 90-day history, pointing to modestly elevated interest relative to normal for the name.
The question heading into October 21 is whether the Q3 print, and more importantly the guidance, can sustain the Barclays and UBS thesis on margin recovery and volume recovery in the biopharma end market.
See the live data behind this article on ORTEX.
Open TMO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
